Microneedle Delivery of Zanamivir for Treatment of Influenza Infections

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AI129122-01A1
Agency Tracking Number: R43AI129122
Amount: $572,526.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA16-302
Timeline
Solicitation Year: 2016
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-03-01
Award End Date (Contract End Date): 2019-03-31
Small Business Information
540 AVIS DR STE A, Ann Arbor, MI, 48108-7906
DUNS: 156551699
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 ELKE LIPKA
 (734) 223-6862
 elipka@tsrlinc.com
Business Contact
 JOHN HILFINGER
Phone: (734) 663-4233
Email: jhilfinger@tsrlinc.com
Research Institution
N/A
Abstract
Abstract Yearly influenza epidemics strike millions of peoplecausing up todeathsFatality caused by most seasonal influenza viruses is ltbut with significant mortality in the young and the elderly populationsWhen a new pathogenic influenza strain enters the populationa pandemic could kill tens of millions of people with a negative economic impact estimated to be overbillion dollarsInfluenza virus is a NIAID category C priority biothreatcharacterized as an emerging agent that is readily available and disseminatedDue to the incomplete efficacy of the current vaccineseffective drug treatment is necessaryPresentlyinfluenza treatment is only somewhat effectiveand some influenza strains are resistant to the currently marketed therapeuticsadamantanes and the neuraminidase inhibitor TamifluHoweverzanamivirRelenzaremains highly active against oseltamivir resistant influenza strainsbut its therapeutic impact is severely limited by its route of administrationvia oral inhalationwhich renders it unsuitable for patients with a compromised respiratory systemThereforedevelopment of a novel delivery alternative for zanamivir as we propose hereis poised to address a significant unmet medical needApplication of a transdermal microneedle delivery strategy to the anti viraland particularly anti influenzamarket offers a number of solutions to large unmet medical needsand represents an attractive market entry strategyTransdermal delivery systems offer a number of improvements over other delivery systemsPatches do not require swallowingeliminating oral side effectsPermeation through the skin allows the drug to directly enter the systemic circulation and avoid any absorption and first pass barriers a drug might encounter with oral deliveryFinallytransdermal delivery avoids skin puncture by syringe needleseliminating pain and patient visits to a physicianTransdermal delivery of ZAN is desirable during an influenza outbreakas large numbers of patients can be reachedThe Phase I portion of this proposal will involve formulation optimization of the prototype patch and subsequent pharmacokinetic and efficacy testing in miceThe final study for this proposal will be a dermatotoxicology studies to assess skin irritation of the final patches in rabbitsThe end result of this work will be a noveltransdermal delivery approach for zanamivir with demonstrated efficacyPK and initial preclinical safety data ready to complete preclinical development activities leading to the opening of an INDWe have assembled a team of expert advisors and collaborators to ensure successful completion of this research plan

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government